

Poster Exhibition

ID	N.pgm	Title	Presenting Author
Ageing			
139	P 1	Ageing in HIV from a gender perspective: results from a survey assessing needs and provisions of care	Luisa Brogonzoli, Milano
187	P 2	Attitudes toward aging and HIV-related stigma in elderly people with HIV	Samuele Gardin, Padova
130	P 3	The Glasgow Manifesto in Italy: A platform for change	Nicoletta Policek, Bruxelles
Basic Science - Immunology			
224	P 4	Elevated levels of interleukin-15 in naïve PLWH normalize earlier for those treated in the primary phase of infection	Giorgio Bozzi, Milano
274	P 5	Evaluation of T cell-mediated immune response after dengue infection: a comparison between people living with HIV and HIV-negative individuals	Pierluigi Francesco Salvo, Roma
98	P 6	Immunomodulatory effects of HIV Tat's N-terminal sequence on CD8+ T cells	Enrico Tassani, Ferrara
270	P 7	The opposite trend of neurotrophins NGF and BDNF during HIV pathogenesis	Luca Maddaloni, Roma
Clinical HIV			
137	P 8	Anal cancer screening in Italy: a pilot survey	Maria Gabriella Dona, Roma
25	P 9	Anal cancer screening uptake in a cohort of women with HIV	Maria Mazzitelli, Padova
310	P 10	Bempedoic Acid and Evolocumab in People Living with HIV: A Real-World Strategy for Achieving LDL Targets in Statin-Intolerant or Reluctant Patients	Marianna Menozzi, Modena
170	P 11	Beyond viral suppression: navigating the polypharmacy maze in elderly people with HIV on antiretroviral therapy	Claudia Gioè, Palermo
277	P 12	Cardiovascular management in PLWH: poor adherence to blood pressure and LDL-C targets	Francesca Chiappini, Chieti
197	P 13	Carotid and femoral intima media thickness (c-IMT and f-IMT): risk stratification for cardiovascular events in PLWH	Giovanbattista Martone, Caserta
49	P 14	Challenging retention in care in HIV-vertically acquired people: a real life experience	Anna D'Angelillo, Roma
3	P 15	Changes in bone mineral density and bone turnover markers in antiretroviral therapy-naïve people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide or doravirine/lamivudine/tenofovir disoproxil fumarate	Leonardo Calza, Bologna
9	P 16	Changes in glucose homeostasis in people living with HIV naïve to antiretroviral therapy and starting dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide	Leonardo Calza, Bologna
337	P 17	Changes in lipid profile and cardiovascular risk after switching to long-acting cabotegravir/rilpivirine	Anna Carraro, Roma
289	P 18	Comorbidities predict longitudinal cognitive changes in People with HIV	Elisa Vuaran, Torino
203	P 19	Correlation between lipid profile, subclinical atherosclerosis and hepatic fibrosteatosis in PLWH: comparison between TAF/FTC/BIC and TDF/3TC/DOR	Ilaria Capriglione, Napoli
285	P 20	Disparities in cardiovascular risk management for PLWH: a comparison of ESC and EACS guidelines	Francesca Chiappini, Chieti
120	P 21	Evolution of liver fibrosis in a cohort of people living with HIV without active hepatitis co-infections	Manuel Crispo, Siena
33	P 22	Glucose homeostasis in People Living With HIV starting long-acting antiretroviral therapy	Alberto Zuppiroli, Bologna
318	P 23	HIV & MASLD burden: longitudinal changes, predictive factors and prognostic impact in people living with HIV from Southern Italy	Antonio Iuliano, Salerno
215	P 24	HIV indicator conditions prior to late presentation: a ten-year analysis in a major clinical center—implications for addressing missed opportunities in one of Italy's top five most affected cities	Gian Carlo Orofino, Torino

Poster Exhibition

ID	N.pgm	Title	Presenting Author
329	P 25	HIV Still Hiding in Reservoirs: Four Cases of Symptomatic CSF Escape with Tenofovir Alafenamide/Emtricitabine/Bictegravir	Carola Lipani, Torino
216	P 26	Implementation of Statin Therapy in an HIV-Positive Cohort: Real-World Challenges and Insights from the REPRIEVE Trial	Chiara Muscatiello, Foggia
324	P 27	Lost to follow-up: what's happened? A single center analysis	Chiara Grillo, Foggia
156	P 28	Management of pregnancy in women living with HIV: a two-week neonatal prophylaxis and breastfeeding experience	Daniela Piacentini, Belluno
200	P 29	Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects in Italy	Francesco Romano, Roma
191	P 30	Metabolic impact of switching TAF/FTC/RPV to BIC/TAF/FTC in a real-life setting	Layla Pagnucco, Pavia
264	P 31	Multidimensional Scale for the Detection of Health Needs in People with HIV: Preliminary Results From the MUSA study	Andrea Calcagno, Torino
173	P 32	Predictors of Hospitalization in HIV Patients: Identifying Key Risk Factors	Livia Moffa, Chieti
290	P 33	Prevalence and predictors of increased creatine phosphokinase (CPK) levels in a cohort of People Living With HIV (PLWH) treated with modern antiretroviral regimens	Margherita Sambo, Siena
251	P 34	Prevalence, predictors and outcomes of poor immunological recovery in PLWH on effective c-ART: a retrospective study from a tertiary University center in Italy	Marina Sarno, Campobasso
111	P 35	Previous COBI-including regimen is the major determinant of lipid profile modification in a cohort of PWH on stable TAF treatment switching to dual treatment	Nicola Squillace, Monza
228	P 36	Re-CALL, Re-TURN, Re-stART: a clinical project for retention in HIV care	Benedetta Trentacapilli, Milano
231	P 37	Screening with GAD-2 in a real-life outpatient setting in Milan. High prevalence of anxiety, associated factors and acceptance of psychologic assessment	Andrea Pastena, Milano
145	P 38	Statin use in people living with HIV without apparent cardiovascular risk factors: observational study of an outpatient cohort	Veronica D'Aquila, Roma
294	P 39	Temporal trends, clinical correlates and prognostic potential of advanced disease in naïve PLWH and impact of COVID-19 pandemic: preliminary results of a 20-year retrospective cohort study	Emanuela Zappulo, Napoli
101	P 40	The role of inflammatory and atherogenic markers in a group of young men living with HIV with erectile dysfunction: a cross-sectional study	Federico Cesanelli, Brescia
307	P 41	Transgender people with HIV: challenges in the ART management	Patrizia Pasculli, Roma
Epidemiology			
69	P 42	A walk on the wild side: an observational retrospective single center study on a cohort of Trans* women coming from Latin America accessing clinics for HIV and STIs in a teaching hospital in Rome	Anastasia Destro, Roma
112	P 43	An HIV Clinic in Bouar, Central African Republic: the cure moves where medical care is missing	Martina Strano, Milano
113	P 44	Antiretroviral therapy in pregnant women living with HIV: real-life data from a tertiary center catering to the greater Milan area, 2019-2025	Margherita Pernich, Milano
201	P 45	Association of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio values with mortality and the occurrence of non-AIDS and AIDS events	Vincenzo Spagnuolo, Milano
164	P 46	Characteristics and clinical outcomes of individuals with HIV and late diagnosis in a healthcare setting in eastern Sicily over the past 15 years	Benedetto Maurizio Celesia, Catania
180	P 47	Clinical characteristics and molecular dynamics of Dengue Cases occurring in Liguria in 2024	Giada Garzillo, Genova
238	P 48	Cluster of primary HIV infections sustained by CRF02_AG in intravenous drug users in Milan	Giorgio Bozzi, Milano



Poster Exhibition

ID	N.pgm	Title	Presenting Author
181	P 49	Co-circulation and co-infection with different influenza viruses in the 2024-2025 FLU season	Giada Garzillo, Genova
295	P 50	Correlation of self-test for HIV bought by pharmacies and regional incidence of HIV in Italy: 2018-2023	Sara Leone, Roma
117	P 51	Drug resistance mutations among ART-naïve individuals in Lecco	Federico Conti, Lecco
192	P 52	Epidemiology of Enteroviruses in Liguria: Analysis of Data from January 2024 to February 2025	Giulia Guarona, Genova
242	P 53	Expanding HCV screening in hospitalized patients: preliminary data of a single centre experience in Monza, Italy	Giulia Ghilardi, Monza
26	P 54	HIV infection in migrants from Sub-Saharan Africa in the North East of Italy	Anna Ferrari, Padova
35	P 55	HIV testing in Italy: preliminary data from three pilot regions of the PRONTI study, 2018-2023	Francesca Centrone, Bari
24	P 56	Interventions to support breastfeeding among mothers living with HIV: a systematic review and meta-analysis	Francesco Di Gennaro, Bari
271	P 57	Investigation on the Continuum of Care in people who inject drug in Italy: the Italian NGOs contribution	Sara Leone, Roma
67	P 58	Low adherence to Post-Exposure Prophylaxis for HIV in people who underwent sexual assault: implementation of a re-call strategy	Arianna Liparoti, Milano
190	P 59	Measles Outbreak in Liguria: Molecular Surveillance and Transmission Dynamics in 2024-2025	Chiada Fracalvieri, Genova
53	P 60	Near full-length sequencing is able to ensure a more accurate HIV-1 subtyping: comparison with commonly used methods	Flavia Smoquina, Roma
245	P 61	Occupational and sexual exposures: analysis of post-exposure prophylaxis (PEP) prescription and surveillance program in a large hospital, Northern Italy	Stefania Arsuffi, Brescia
284	P 62	Prevalence and incidence trends of AIDS events in people newly diagnosed with HIV infection before and after COVID-19 pandemic: experience from the Pisan cohort	Mario Cesaretti, Pisa
91	P 63	Respiratory pathogen profile and its association with hospitalization risk in paediatric patients with acute respiratory infection (ARI): Inpatient and outpatient comparison	Rossana Scutari, Roma
266	P 64	Testing for HIV and other sexual transmitted diseases offered in the context of community based voluntary counselling and testing services in the last years in Italy (2019-2023)	Alessandro Caioli, Roma
Hepatitis and Liver Diseases			
214	P 65	A model of screening and cascade of care for chronic viral hepatitis in asylum seekers and refugees in Rome	Giulia Quartini, Terni
163	P 66	Bulevirtide treatment in people living with HIV/HBV/HDV coinfection	Cecilia Giuliani, Pavia
259	P 67	Characterization of a cohort of liver transplant patients for HBV and/or HBV/HDV related complications: results of a Campania multicenter study	Lorenzo Salmoni, Napoli
225	P 68	Clinical and instrumental changes of liver function after one year of bulevirtide treatment in Chronic Hepatitis Delta with advanced hepatic disease: insight from a Monocentric Cohort study	Alberto Zuppiroli, Bologna
19	P 69	Clinical and virological features of chronic HBV infected patients with genotype E	Maria Alberti, Brescia
2	P 70	Comparative investigation on the implementation of the national screening program for HCV in Italian regions	Massimiliano Conforti, Torino
147	P 71	Evaluating integrated healthcare pathways for HCV elimination: a pilot study from a large Italian region	Erica De Vita, Pisa
252	P 72	Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history and careful monitoring of viral markers	Marianna Menozzi, Modena

Poster Exhibition

ID	N.pgm	Title	Presenting Author
118	P 73	Long-term outcomes and incidence of clinically significant events after HCV eradication in people with HIV: data from ICONA/HepaICONA cohorts	Maria Mazzitelli, Padova
143	P 74	Optimizing hepatitis C treatment: the impact of patient reported measures in varied healthcare settings in a large Italian region	Erica De Vita, Pisa
144	P 75	Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex ebx071 and Altostar	Sara Uceda Renteria, Milano
182	P 76	The substantial burden of HDV chronic infection and the gaps in HDV screening across Europe rise the need to implement HDV diagnostics at pan-European level	Ilaria Grossi, Roma
195	P 77	Treatment of chronic HDV hepatitis with bulevirtide: preliminary results of a behavior-driven investigation on patients and clinicians	Lorenzo Badia, Bologna
331	P 78	Trends in the prevalence and epidemiological characteristics of HDV infection in HBsAg+ persons with or without HIV in Italy: is HIV still a key factor for HDV co-infection?	Massimo Puoti, Milano
220	P 79	Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure	Alessandro Soria, Monza
142	P 80	Utility of the Fibrosis-4 Index for 10-Year Risk of All-Cause Mortality in People with HIV: A Retrospective Longitudinal Cohort Study	Costanza Bertoni, Milano
HIV: Antiretroviral therapy			
168	P 81	Acceptance rate and reasons for rejection of long-acting injectable CAB/RPV in an Italian center	Alessandra Vergori, Roma
38	P 82	Antiretroviral therapy in patients with swallowing disorders: an open issue	Norma Spalletta, Roma
332	P 83	B/F/TAF as a switch therapy in a cohort of women living with HIV: a 24-months observational study on durability, effectiveness and metabolic profile	Raffaella Marocco, Latina
92	P 84	Bictegravir/tenofovir alafenamide/emtricitabine: a real-life experience in Women Living With HIV (WLWH)	Anna Gidari, Terni
66	P 85	Causes of discontinuation of co-formulated DOR/TDF/3TC in ART-experienced adults with HIV-1 after three years of follow-up: Real-world data from a single center in Florence, Italy	Giuseppe Formica, Firenze
268	P 86	Changes in body weight in people living with HIV switching therapy from TAF/FTC/RPV to TAF/FTC/BIC	Rebecca Jo Steiner, Roma
45	P 87	Dual versus triple as optimization antiretroviral therapy in people with HIV with stable virological suppression: long-term effectiveness from the MOSAICO Study	Giacomo Berti, Padova
306	P 88	Effectiveness and durability of simplification strategies with oral dolutegravir/lamivudine vs long-acting injectable cabotegravir/rilpivirine in virologically suppressed people living with HIV	Andrea Carbone, Roma
243	P 89	Immunovirological efficacy of long-acting cabotegravir/rilpivirine therapy and perception of well-being in people living with HIV. Experience of the Infectious Diseases Clinic of Perugia	Elisabetta Schiaroli, Perugia
239	P 90	Impact of 2 drug antiretroviral regimens on immune recovery	Rebecca Jo Steiner, Roma
227	P 91	Impact of baseline plasma HIV-1 RNA and viral subtype on the achievement of virological suppression in PWH treated with bictegravir/emtricitabine/tenofovir alafenamide in clinical practice	Lorenzo Crupi, Genova
308	P 92	Implementation of a same-day ART start model in a real-life setting: experiences from a clinical centre in Italy	Giulia Micheli, Roma
149	P 93	Lipid profile improvement among ART-experienced PLWH switching to Bictegravir/Emtricitabine/Tenofovir alafenamide according to prior INSTI exposure and latest ART regimen	Nicola Colavito, Bari

Poster Exhibition

ID	N.pgm	Title	Presenting Author
56	P 94	Long-acting injectable antiretroviral therapy (LAI-ART) with cabotegravir (CAB) and rilpivirine (RPV) for the treatment of HIV infection: analysis nearly two years implementation in a university hospital	Francesca Saveria Soave, Parma
76	P 95	Metabolic and Immunological Outcomes After Switching to Long-Acting Cabotegravir + Rilpivirine: A 44-Week Multicenter Observational Study (LAHIV)	Filippo Lagi, Firenze
97	P 96	Minor revision: simplification therapy with dolutegravir, a retrospective observational study with 96 weeks follow-up	Anita Pupo, Roma
275	P 97	Next Generation Sequencing (NGS) of proviral HIV DNA and analysis of APOBEC-induced mutations to assess suitability for long-acting cabotegravir/rilpivirine therapy	Giovanni Massobrio, Genova
249	P 98	Patient-reported outcomes in HIV: a study on quality of life in PLWH on long-acting antiretroviral therapy	Antonio Auricchio, Campobasso
212	P 99	Proximity-based long-acting therapy: a real-world model at a clinical center for HIV/AIDS care in Turin	Gian Carlo Orofino, Torino
309	P 100	Real-life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with more than 50 years old	Giulia Moi, Sassari
322	P 101	Real-World Durability, Safety, and Changes in Lipid and Body Weight Profiles with B/F/TAF in ART- Naive Adults: A 24-Month Observational Study	Giulia Mancarella, Latina
166	P 102	Sculpting long-term success in hiv therapy: the synergistic dynamics of dolutegravir and doravirine in a precision-driven dual regimen	Federica Zimmerhofer, Palermo
267	P 103	Switching boosted protease inhibitor-based antiretroviral therapy to fostemsavir plus an optimized background in people with HIV with limited therapeutic options: a case series from the FOST SWITCH Study	Andrea Calcagno, Torino
218	P 104	Switching from 3 or 2-drug oral regimen to Long-Acting Cabotegravir and Rilpivirine in People With HIV: Real-World Experience from ASST Lecco	Martina Bottanelli, Lecco
177	P 105	Treatment interruption among PWH on long-acting-injectable (LAI) Cabotegravir/Rilpivirine: Experience from an Italian HIV Outpatient clinic	Gloria Sangaletti, Pavia
205	P 106	Up to half of geriatric people living with HIV are treated with 2-drug INSTI-based regimens	Diego Ripamonti, Bergamo
89	P 107	Use of prolonged-release injectable CAB/RPV in outpatients	Nicoletta Bobbio, Genova
122	P 108	Virological failures in a real-world cohort: a retrospective analysis of population characteristics and resistance mutations	Claudio Rigamonti, Bologna
Infections in the Immunocompromised Host			
253	P 109	Circulating autoantibodies targeting G-protein-coupled neurotransmitter receptors: reliable biomarkers for Long COVID diagnosis?	Marta Camici, Rome
171	P 110	Early management of COVID-19 infection in solid organ transplant recipients: our experience with antiviral treatments	Federica Guida Marascia, Palermo
288	P 111	Long COVID: looking for a definition	Viola Cogliandro, Monza
125	P 112	Long-term neurological outcome in Progressive Multifocal Leukoencephalopathy survivors	María del Carmen García Martearena, Milano
240	P 113	Non-tuberculous mycobacteria (NTM) in people with HIV (PWH) in recent cART era: clinical presentation and mortality	Flavia Sanmartin, Roma
291	P 114	Prolonged clinical monitoring of cognitive performance and psychiatric symptoms among PACS	Giulia Del Duca, Roma
94	P 115	SARS-CoV-2 infection in hospitalized oncohematological patients: a comparison between two years	Francesco Izzo, Roma
281	P 116	Specific T-cell response to CMV, EBV and VZV in people with multiple sclerosis under disease-modifying therapies	Federica Dominelli, Roma

Poster Exhibition

ID	N.pgm	Title	Presenting Author
296	P 117	Trajectories and Predictors of Post-COVID-19 Condition Persistence: a prospective evaluation in the EuCARE Study	Andrea Santoro, Milano
74	P 118	Unraveling the role of peripheral and mucosal SARS-CoV-2-specific CD8 T cell responses in shaping disease severity	Elena Adelina Gabor, Parma
172	P 119	Varicella Zoster Virus Vaccination in patients with haematological diseases and primary immunodeficiencies. Assessment of specific T and B-cell responses	Luigi Coppola, Roma
141	P 120	Viral respiratory infections in immunocompromised and immunocompetent patients: a case-control study	Martina Mastropaolo, Roma
162	P 121	What remains of Long COVID after four years from hospitalization for severe COVID pneumonia	Viola Cogliandro, Monza
PrEP			
297	P 122	Assessment and monitoring of psychological, sexual, and relational status in individuals accessing a Pre-Exposure Prophylaxis (PrEP) program	Giulia Del Duca, Roma
129	P 123	Exploring the attitude about using telehealth in persons on Pre-Exposure Prophylaxis (PrEP)	Lolita Sasset, Padova
90	P 124	HIV PrEP and STI Surveillance: insights from a Tertiary HIV Unit	Francesco Barbaro, Padova
18	P 125	Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey	Silvia Nozza, Milano
248	P 126	Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified PrEP delivery	Pietro Leone Giovanni Vinti, Milano
104	P 127	PrEP - Where are we now? Understanding providers' perspectives on current practices and long-acting PrEP in Southern Italy	Mariacristina Polisenio, Bari
30	P 128	The role of Ancona Checkpoint in counseling and facilitating PrEP access through tele-visits	Sara Caucci, Ancona
Social Science, PROs			
283	P 129	Acceptability and availability to change care for people living with HIV followed by home care assistance (HCA)	Valentina Iannone, Roma
6	P 130	Analysis of the final data and future prospects of the "FRAGIL/mind" project	Angela Calluso, Bari
246	P 131	Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals	Rosario Galipò, Roma
14	P 132	Anlaids Forum challenges Artificial Intelligence: can algorithms act as a counsellor?	Alberto Venturelli, Roma
11	P 133	Assessing awareness of HIV and prevention strategies: a cross-sectional study from two free rapid testing events in Rome	Luca Bortolani, Roma
136	P 134	Beyond a standalone checkpoint: Three years of collaboration and growth at IOC'ENTRO, Genoa, Italy	Allegra Ferrari, Genova
325	P 135	Bridging gaps in HIV care: an outreach screening program for street-based sex workers	Alessandro Soria, Monza
175	P 136	Challenges on Recruiting for the HIV-CORE 007 Cure Trial: the perspective of Infectious Disease Doctors	Elena Bruzzesi, Milano
210	P 137	Degree of appropriateness and organization of services dedicated to the administration of CAB+RPV: PWH opinions from an Italian multicenter cohort	Giuseppe Cucinotta, Roma
303	P 138	Degree of current knowledge and awareness regarding long-acting injectable antiretroviral therapy in people living with HIV who are undergoing oral therapy	Valentina Iannone, Roma
1	P 139	Evolution of HIV Testing Access in the MSM Community: a Comparison of the 2005/2015 and 2015/2025 Decades with a Focus on the Use of the INSTI Test in Meeting Places (Outreach)	Matteo Corda, Milano

Poster Exhibition

ID	N.pgm	Title	Presenting Author
138	P 140	From screening to care: Strengthening linkage to services for marginalized populations in Genoa, Italy	Gloria Notore, Genova
87	P 141	Getting to the first 95: introducing recommended best practices in national HIV testing guidelines	Paolo Russo, Milano
21	P 142	HIV and STI testing beyond key populations: Brescia's first community-based experience	Marco Stizioli, Brescia
10	P 143	LILA's virtual help desk: giving voice and empowering people with HIV through remote support	Giacomo Dessi, Cagliari
219	P 144	Multifactorial vulnerability and HIV: local response to health-care needs of key populations	Marco Falaguasta, Padova
64	P 145	New challenges in the long-term management of people living with HIV (PLWH): introduction of Patient-Reported Outcomes (PROs) into routine clinical practice. A pilot study	Daniela Segala, Ferrara
250	P 146	Patient-reported outcomes (PROs) in people living with HIV treated with long-acting injectable antiretroviral therapy (LAI-ART)	Stefano Rapino, Brescia
77	P 147	People living with HIV in treatment with long-acting therapy: what changes in terms of stigma?	Annunziata Romeo, Torino
13	P 148	PrEP is an obstacle race	Brunella Mocci, Cagliari
196	P 149	Promoting health through movement: fit-walking as an intervention to reduce cardiovascular and metabolic risk in people living with HIV/AIDS in Turin	Gian Carlo Orofino, Torino
301	P 150	Psychological outcomes and learning loss in students after the COVID-19 pandemic: findings from EuCARE's SCHOOL studies	Francesca Incardona, Roma
135	P 151	School intervention for STIs prevention 2024-2025	Paolo Marco Testoni, Milano
193	P 152	Sexualized drug use and chemsex: exploring the link between addiction, sexual risk, and psychological well-being among MSM in Modena, Italy	Gianluca Cuomo, Modena
140	P 153	Streethaart project: art as a tool to challenge Stigma and promote well-being among people living with HIV	Carlo Oneto, Napoli
342	P 154	The impact of awareness-raising and screening initiatives on the migrant population living in Bergamo	Ilaria Mercurio , Bergamo
16	P 155	The need and frequency of STI testing depends on the lifestyle of the people on PrEP. Data from the PrEP Point Plus (PPP) in Bologna	Sandro Mattioli, Bologna
328	P 156	Therapeutical group for chemsex addiction	Giorgia Fracca, Milano
STIs			
302	P 157	Doxycycline vs Penicillin for Late Latent Syphilis: Comparative Analysis of Efficacy data	Damiano Farinacci, Roma
86	P 158	Dynamics of syphilis among HIV+: prevalence, incidence and serological results in 1669 PLWH, 2021-23, "D. Cotugno" hospital, Naples	Francesco Maria Fusco, Napoli
299	P 159	Dynamics of vaccine-preventable anal HPV genotypes in individuals screened for HPV: a retrospective observational study	Alberto Rizzo, Milano
333	P 160	HPV and STIs screening in outpatient clinic. The multidisciplinary experience in AOUP- Pisa (preliminary data)	Laura Del Bono, Pisa
28	P 161	Impact of genotypic substitutions on treatment failure for Mycoplasma genitalium infection	Nicholas Brian Bana, Milano
124	P 162	Investigation of Additional Risk Factors to Prioritize Anal Cancer Screening in MSM Living With HIV	Eugenio Nelson Cavallari, Roma
258	P 163	More Testing, More STDs? The paradox of follow-up in people on PrEP	Damiano Farinacci, Roma

Poster Exhibition

ID	N.pgm	Title	Presenting Author
127	P 164	Outcomes of Anal High Grade Dysplasia Treatment in MSM living with HIV and MSM living without HIV	Eugenio Nelson Cavallari, Roma
55	P 165	Prevalence of syphilis among people living with HIV (PLWH), pre-exposure prophylaxis (PrEP) users and individuals screened for sexually transmitted disease (STD) attending Ferrara HIV/AIDS Section. A comparative observational study	Daniela Segala, Ferrara
222	P 166	Scabies: not just a neglected disease, but a public health concern among key populations	Giulia Lenzi, Roma
48	P 167	Sexually transmitted infections, condom use and sexual behaviors in women: the WomanIST experience in an Italian reference center	Giada Canavesi, Legnano
Vaccines			
188	P 168	A Rapid Fluorometric Approach for Evaluating ADCC Activity Against Different forms of HIV-1 Env Protein	Mara Martino, Ferrara
334	P 169	Comparison of STI burden and its predictors in people diagnosed with mpox or vaccinated with MVA-BN	Alessandro Giacinta, Roma
206	P 170	Current adherence and vaccine hesitancy to Herpes Zoster vaccination in northern Italy: a cumulative trend analysis at an HIV clinical center in Turin	Gian Carlo Orofino, Torino
44	P 171	Evaluating the long-term antibody response of MVA-BN in people living with HIV (PLWH): a two-year monocentric follow-up study	Pierluigi Francesco Salvo, Roma
43	P 172	Evaluation of virologic rebounds in people living with HIV (PLWH) after receiving MVA-BN vaccination for mpox	Pierluigi Francesco Salvo, Roma
323	P 173	Hepatitis B vaccine response in people living with HIV and with isolated anti-HBc serological profile: a retrospective study	Emanuele Guarise, Genova
236	P 174	Multi-cytokine assessment of T-cell responses to Varicella Zoster Virus glycoprotein E after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatments	Livia Benedetti, Roma
237	P 175	The impact of vaccination on presentation and clinical outcomes in patients hospitalized for COVID-19 Pneumonia in a Lombardy Tertiary Care Center	Nicole Gemignani, Lecco
Virology and Pharmacology			
208	P 176	Evaluation of AD4SEQ HIV-1 Whole Genome for Drug Resistance Testing	Federica Stefanelli, Genova
204	P 177	Exploring the relationship between HIV-DNA load and archived antiretroviral drug resistance in treated individuals with suppressed or low-level viremia	Daniele Armenia, Roma
211	P 178	HIV-1 Whole Genome Sequencing: comparative analysis of Illumina and Nanopore technologies	Federica Stefanelli, Genova
340	P 179	HIV-DNA Analysis in PLWH with a complex treatment history: correlation with immunological and virological parameters	Roberta Campagna, Roma
82	P 180	In vitro characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degradator of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2	Mirko Giuseppe Liturri, Milano
107	P 181	Injection site pain and cabotegravir/rilpivirine trough plasma concentration in people with HIV	Caterina Candela, Milano